Cochrane · systematic review · CD005262
Pentoxifylline for intermittent claudication
Broderick, C, Forster, R, Abdel-Hadi, M, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
VascularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 60%Moderate 2 · 40%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Pentoxifylline compared with placebo for treatment of people with intermittent claudication
Population: people with intermittent claudication
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
PFWD (change in metres) (4–40 weeks' Pentoxifylline vs placebo | no estimate extracted | 11 studies · 1890 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
TWD (change in metres) (8–52 weeks' Pentoxifylline vs placebo | no estimate extracted | 14 studies · 2110 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
ABI (pre‐exercise/baseline ABI compared with Pentoxifylline vs placebo | no estimate extracted | 5 studies · 902 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
QoL (SF‐36, WIQ and unspecified) (1 study with 4 weeks' Pentoxifylline vs placebo | no estimate extracted | 3 studies · 1179 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Side effects (number of cases or proportion) (4–52 weeks' Pentoxifylline vs placebo | no estimate extracted | 9 studies · 1837 participants | Low Downgraded: risk of bias, imprecision, inconsistency |